TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12434648

Group type: EXPERIMENTAL
Intervention: Midodrine 10 mg per os
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 9884251

Group type: EXPERIMENTAL
Intervention: Neoral
Number of subjects: 390

Group type: COMPARATOR
Intervention: Sandimmun
Number of subjects: 390
Study: 7640495

Group type: EXPERIMENTAL
Intervention: Alcohol extraction of Abelmoschus manihot, Gliclazide and Captopril tablets
Number of subjects: 68

Group type: COMPARATOR
Intervention: Gliclazide and Captopril tablets
Number of subjects: 68
Study: 2719459

Group type: EXPERIMENTAL
Intervention: Ofloxacin 400 mg orally
Number of subjects: 201

Group type: COMPARATOR
Intervention: Amoxicillin 3.0 g plus probenecid 1.0 g orally
Number of subjects: 201
Study: 385458

Group type: EXPERIMENTAL
Intervention: 1 g cimetidine per day
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (identical tablets containing lactose)
Number of subjects: 60
Study: 31389308

Group type: EXPERIMENTAL
Intervention: Lower than optimum power load (LOPL; 20% lower than OPL)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Higher than optimum power load (HOPL; 20% higher than OPL)
Number of subjects: 23
Study: 31150953

Group type: EXPERIMENTAL
Intervention: Paid Family Leave (PFL) policy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control groups
Number of subjects: 0
Study: 29109658

Group type: EXPERIMENTAL
Intervention: Single-needle arthrocentesis with distension of the upper compartment of the TMJ (1N)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Conventional two-needle arthrocentesis (2N)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both techniques (1N and 2N)
Number of subjects: 26
Study: 25609940

Group type: EXPERIMENTAL
Intervention: Glycopyrronium 50 μg once daily
Number of subjects: 460

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 460
Study: 22453076

Group type: EXPERIMENTAL
Intervention: Fasting capillary blood glucose (FCG) measurement
Number of subjects: 993

Group type: COMPARATOR
Intervention: Fasting venous plasma glucose (FPG) measurement
Number of subjects: 993
Study: 21086010

Group type: EXPERIMENTAL
Intervention: Training with low level laser therapy (LLLT)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Training only (TG)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Training with LLLT (TLG)
Number of subjects: 36
Study: 19494484

Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) 300 U/kg intravenously before surgery
Number of subjects: 71

Group type: COMPARATOR
Intervention: Saline (placebo) intravenously before surgery
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO)
Number of subjects: 71
Study: 18037816

Group type: EXPERIMENTAL
Intervention: Nicotine skin patch
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 10
Study: 15514884

Group type: EXPERIMENTAL
Intervention: Profile preparation of the root canal with maillefer thermafil filling (Group A)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Profile preparation of the root canal with iodoform cataplasm and gutta percha filling (Group B)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preparation of the root canal with stainless steel hand-operated instruments, iodoform cataplasm and gutta percha filling (Group C)
Number of subjects: 0
Study: 11294487

Group type: EXPERIMENTAL
Intervention: Selective Serotonin Reuptake Inhibitors (SSRIs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tricyclic Antidepressants (TCAs)
Number of subjects: 0
Study: 9405581

Group type: EXPERIMENTAL
Intervention: Oral administration of [13C5] and [2H2]folic acid (approximately 500 nmol each)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Intravenous administration of [2H2]folic acid (226 nmol)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Oral administration of [13C5]folic acid (1010 nmol)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Comparison of intravenous vs oral doses
Number of subjects: 4
Study: 8131770

Group type: EXPERIMENTAL
Intervention: TTS-NG (transdermal nitroglycerin) 10 mg.24 h-1
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: TTS-NG + BNZ (benazepril 10 mg b.i.d.)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 3314877

Group type: EXPERIMENTAL
Intervention: Psychological intervention
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Social support program
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control program (no adjunct treatment)
Number of subjects: 53
Study: 31297739

Group type: EXPERIMENTAL
Intervention: Percutaneous repair with MitraClip®
Number of subjects: 921

Group type: COMPARATOR
Intervention: Optimal medical therapy
Number of subjects: 921

Group type: EXPERIMENTAL
Intervention: Transcatheter treatment with MitraClip®
Number of subjects: 921

Group type: COMPARATOR
Intervention: Control group (optimal medical therapy)
Number of subjects: 921
Study: 28075038

Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention (EX) for 24 weeks
Number of subjects: 19

Group type: COMPARATOR
Intervention: Usual lifestyle control (CON)
Number of subjects: 19
Study: 27125909

Group type: EXPERIMENTAL
Intervention: Ubiquinol-10 (150 mg/day)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 25336745

Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention (ILI)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Diabetes Support and Education (DSE)
Number of subjects: 92
Study: 22219012

Group type: EXPERIMENTAL
Intervention: Conventional laparoscopic surgery (CLS)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: SPLS using one pre-bent and one straight laparoscopic instrument (SPLS-ps)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: SPLS using two pre-bent instruments (SPLS-pp)
Number of subjects: 90

Group type: COMPARATOR
Intervention: SPLS (both groups)
Number of subjects: 90
Study: 20527343

Group type: EXPERIMENTAL
Intervention: 0.5% levobupivacaine
Number of subjects: 46

Group type: COMPARATOR
Intervention: 0.5% ropivacaine
Number of subjects: 46
Study: 18606901

Group type: COMPARATOR
Intervention: Paricalcitol 0 microg (placebo)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Paricalcitol 1 microg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Paricalcitol 2 microg
Number of subjects: 24
Study: 15682005

Group type: EXPERIMENTAL
Intervention: Custom soft orthoses
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Semirigid biomechanical orthoses
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Simple shoe inserts
Number of subjects: 404

Group type: COMPARATOR
Intervention: Overall incidence of back pain
Number of subjects: 404
Study: 12569288

Group type: EXPERIMENTAL
Intervention: Dacarbazine (250 mg/m(2) days 1‐5 every 3 weeks) plus tamoxifen
Number of subjects: 125

Group type: COMPARATOR
Intervention: Vindesine (3 mg/m(2) every week for 6 weeks, then every 2 weeks) plus tamoxifen
Number of subjects: 125
Study: 10929906

Group type: EXPERIMENTAL
Intervention: Quantitative hepatobiliary scintigraphy (QHBS)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Endoscopic sphincter of Oddi manometry (ESOM)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (asymptomatic cholecystectomized patients)
Number of subjects: 20
Study: 8794599

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 138

Group type: COMPARATOR
Intervention: Lofepramine
Number of subjects: 138
Study: 1352050

Group type: EXPERIMENTAL
Intervention: Remoxipride (150-300 mg daily)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Remoxipride
Number of subjects: 62
Study: 6371649

Group type: EXPERIMENTAL
Intervention: Bichromatic argon laser therapy (multiple wavelengths: 454.5 nm to 528.7 nm)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Monochromatic argon laser therapy (green wavelength at 514.5 nm)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Comparison between bichromatic and monochromatic laser therapy
Number of subjects: 100
Study: 3540025

Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 29744621

Group type: EXPERIMENTAL
Intervention: B-mode ultrasound
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: RF echo tracking
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: RF speckle probability distribution
Number of subjects: 120
Study: 29126396

Group type: EXPERIMENTAL
Intervention: Structured, individualized endurance training and nutrition education based on the Mediterranean diet for 3 months, plus monthly group training and regular telephone contact during the subsequent 9 months
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group attended one session on healthy nutrition and the benefits of physical activity
Number of subjects: 68
Study: 25930236

Group type: EXPERIMENTAL
Intervention: Comprehensive intervention
Number of subjects: 751

Group type: COMPARATOR
Intervention: Delayed partial intervention
Number of subjects: 751

Group type: COMPARATOR
Intervention: ZDHS orphans
Number of subjects: 751

Group type: COMPARATOR
Intervention: All orphan groups
Number of subjects: 751
Study: 24157432

Group type: EXPERIMENTAL
Intervention: Exercise training during hemodialysis (40 min/session for 3 months)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Exercise training during hemodialysis
Number of subjects: 35
Study: 21426751

Group type: EXPERIMENTAL
Intervention: Coronary artery disease (CAD) group (25 patients, 20M/5F, mean age 61.2 ± 10.4 years)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Non-CAD group (20 patients, 8M/12F, mean age 57.8 ± 13.3 years)
Number of subjects: 45
Study: 18510068

Group type: EXPERIMENTAL
Intervention: Local infiltrative anesthesia using 2% lidocaine with adrenaline (1:200,000)
Number of subjects: 58

Group type: COMPARATOR
Intervention: No local infiltrative anesthesia with adrenaline (Control)
Number of subjects: 58
Study: 16513672

Group type: EXPERIMENTAL
Intervention: Intrabrachial infusions of noradrenaline (NA)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Intrabrachial infusions of tyramine (TYR)
Number of subjects: 19
Study: 11983727

Group type: EXPERIMENTAL
Intervention: Transdermal testosterone (2-2.5 mg patches/d)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 67
Study: 9806692

Group type: EXPERIMENTAL
Intervention: Proglumide
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 8552887

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 2714912

Group type: EXPERIMENTAL
Intervention: oral atenolol (100 mg per day)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: oral verapamil (80 mg three times per day)
Number of subjects: 43
Study: 318849

Group type: EXPERIMENTAL
Intervention: Lignocaine, etidocaine, and bupivacaine in 10-ml doses of plain solutions
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 67
Study: 31320738

Group type: EXPERIMENTAL
Intervention: ranibizumab treatment
Number of subjects: 367
Study: 29969750

Group type: EXPERIMENTAL
Intervention: Pheochromocytoma
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Highest urinary normetanephrine quartile
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Increasing urinary normetanephrine quartile categories
Number of subjects: 295
Study: 27740883

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Intervention (CBI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 25439413

Group type: COMPARATOR
Intervention: ondansetron 4 mg (Group O4)
Number of subjects: 135

Group type: COMPARATOR
Intervention: ramosetron 0.3 mg (Group R)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: ondansetron 8 mg (Group O8)
Number of subjects: 135
Study: 22475819

Group type: EXPERIMENTAL
Intervention: Higher net endogenous acid production
Number of subjects: 632

Group type: EXPERIMENTAL
Intervention: Net endogenous acid production
Number of subjects: 632
Study: 20560920

Group type: EXPERIMENTAL
Intervention: Intersurgical Solus laryngeal mask airway (LMA)
Number of subjects: 120

Group type: COMPARATOR
Intervention: i-gel
Number of subjects: 120
Study: 18391564

Group type: EXPERIMENTAL
Intervention: Electrical ear canal stimulation (ECS)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Preoperative residual hearing (nonamplified and amplified)
Number of subjects: 18
Study: 15908851

Group type: EXPERIMENTAL
Intervention: Telephone or audio computer‐assisted self‐interview (ACASI)
Number of subjects: 588

Group type: EXPERIMENTAL
Intervention: Asking about future intentions before asking about the behavior
Number of subjects: 588
Study: 12952109

Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 460

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 460
Study: 10336575

Group type: EXPERIMENTAL
Intervention: Mizolastine 10 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Mizolastine 20 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Mizolastine 40 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 7577307

Group type: EXPERIMENTAL
Intervention: Enhanced intervention
Number of subjects: 381

Group type: COMPARATOR
Intervention: Standard intervention
Number of subjects: 381
Study: 2044648

Group type: EXPERIMENTAL
Intervention: Cholestyramine (24 g daily in divided doses) plus moderate cholesterol-lowering diet
Number of subjects: 3806

Group type: COMPARATOR
Intervention: Placebo plus moderate cholesterol-lowering diet
Number of subjects: 3806
Study: 7006620

Group type: EXPERIMENTAL
Intervention: 5 mg xipamide per day
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 40 mg xipamide per day
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: All doses of xipamide
Number of subjects: 30
Study: 29460509

Group type: EXPERIMENTAL
Intervention: Carboxytherapy in Group IA (AA patients)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Carboxytherapy in Group IIA (AGA patients)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo in Group IB (AA patients)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo in Group IIB (AGA patients)
Number of subjects: 80
Study: 27876079

Group type: EXPERIMENTAL
Intervention: Circle of Security-Parenting (COS-P)
Number of subjects: 314

Group type: COMPARATOR
Intervention: Care as Usual (CAU)
Number of subjects: 314
Study: 24833263

Group type: EXPERIMENTAL
Intervention: Concentric training (CON)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Eccentric training (ECC)
Number of subjects: 22
Study: 22720051

Group type: EXPERIMENTAL
Intervention: Twice‐weekly, school‐based jumping regime
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 29
Study: 20042191

Group type: EXPERIMENTAL
Intervention: Low Lys:Arg ratio diet (0.7)
Number of subjects: 30

Group type: COMPARATOR
Intervention: High Lys:Arg ratio diet (1.4)
Number of subjects: 30
Study: 18811118

Group type: EXPERIMENTAL
Intervention: Corneal collagen cross-linking (CXL) with 0.1% riboflavin and UVA irradiation (370 nm, 3 mW/cm2, 30 min)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 49
Study: 16043121

Group type: EXPERIMENTAL
Intervention: CXCR3 polymorphism c.12+234G > A
Number of subjects: 0
Study: 12455115

Group type: EXPERIMENTAL
Intervention: 1% ropivacaine without adrenalin but with 10 U/mL of hyaluronidase (Group RH)
Number of subjects: 100

Group type: COMPARATOR
Intervention: 1% ropivacaine without adrenalin and without hyaluronidase (Group R)
Number of subjects: 100
Study: 10744344

Group type: EXPERIMENTAL
Intervention: rHuEPO 30 IU/kg bodyweight
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: rHuEPO 60 IU/kg bodyweight
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: rHuEPO 100 IU/kg bodyweight
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: rHuEPO (all doses)
Number of subjects: 9
Study: 8905242

Group type: EXPERIMENTAL
Intervention: Paracetamol 500 mg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Paracetamol 750 mg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Paracetamol 1000 mg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Paracetamol 1250 mg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Paracetamol 1500 mg
Number of subjects: 5
Study: 1648944

Group type: EXPERIMENTAL
Intervention: Intermittent bolus infusion of metoclopramide (1 mg/kg, 30 min, every 8 h, day 1-5)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Continuous infusion of metoclopramide (3 mg/kg/24 h, 120 h)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Continuous infusion of metoclopramide
Number of subjects: 21

Group type: COMPARATOR
Intervention: Intermittent bolus infusion of metoclopramide
Number of subjects: 21
Study: 7136436

Group type: EXPERIMENTAL
Intervention: Suprapubic bladder drainage using an indwelling Silastic catheter
Number of subjects: 0

Group type: COMPARATOR
Intervention: Transurethral catheterization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Suprapubic bladder drainage
Number of subjects: 0
Study: 31970581

Group type: EXPERIMENTAL
Intervention: Perceived drug-related stigma measures
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Internalized drug-related stigma measures
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: HIV-related stigma
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Drug-related stigma
Number of subjects: 241
Study: 30790587

Group type: EXPERIMENTAL
Intervention: DSAEK with preoperative ECD
Number of subjects: 1007

Group type: EXPERIMENTAL
Intervention: DSAEK with ECD at 6 months
Number of subjects: 1007

Group type: EXPERIMENTAL
Intervention: Operative complications during DSAEK
Number of subjects: 1007

Group type: EXPERIMENTAL
Intervention: Graft dislocation during DSAEK
Number of subjects: 1007
Study: 28131045

Group type: EXPERIMENTAL
Intervention: EPA (2.7 g/d)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: DHA (2.7 g/d)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Corn oil (3 g/d)
Number of subjects: 154
Study: 27004292

Group type: EXPERIMENTAL
Intervention: Immediate Loading (IL)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Delayed Loading (DL)
Number of subjects: 30
Study: 24961021

Group type: EXPERIMENTAL
Intervention: 6% HES 130/0.4
Number of subjects: 50

Group type: COMPARATOR
Intervention: 3% modified fluid gel
Number of subjects: 50
Study: 22226431

Group type: EXPERIMENTAL
Intervention: Topical eflornithine hydrochloride
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 20074751

Group type: EXPERIMENTAL
Intervention: Endothelin‐A subtype receptor antagonist sitaxsentan at 1 mg/kg
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Endothelin‐A subtype receptor antagonist sitaxsentan at 2 mg/kg
Number of subjects: 29

Group type: COMPARATOR
Intervention: Vehicle (saline)
Number of subjects: 29
Study: 17684988

Group type: EXPERIMENTAL
Intervention: Agents containing succinic and fumaric acids (Group 1, n = 11)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Infusion therapy (Group 2, n = 11)
Number of subjects: 22
Study: 16229647

Group type: EXPERIMENTAL
Intervention: 405 nm violet diode laser (continuous on-axis)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 670 nm red diode laser (continuous on-axis)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 405 nm violet diode laser (flickering or off-axis)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 670 nm red diode laser (flickering or off-axis)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 405 nm violet diode laser (eccentric targets)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 670 nm red diode laser (eccentric targets)
Number of subjects: 0
Study: 11874928

Group type: EXPERIMENTAL
Intervention: Intensive dietary and exercise program
Number of subjects: 79

Group type: COMPARATOR
Intervention: Modest dietary and exercise program (control)
Number of subjects: 79
Study: 10201429

Group type: EXPERIMENTAL
Intervention: Memory guided saccades
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Memory guided pointing
Number of subjects: 1
Study: 8499823

Group type: EXPERIMENTAL
Intervention: Amoxycillin once daily
Number of subjects: 157

Group type: COMPARATOR
Intervention: Phenoxymethylpenicillin three or four times a day
Number of subjects: 157
Study: 3306508

Group type: EXPERIMENTAL
Intervention: LHRH agonist
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study: 31729550

Group type: EXPERIMENTAL
Intervention: Low dose fentanyl infusion (1 mcg/kg/hr)
Number of subjects: 58

Group type: COMPARATOR
Intervention: 24% oral sucrose (2 ml)
Number of subjects: 58
Study: 30377118

Group type: EXPERIMENTAL
Intervention: Moderate exercise for 30 min at 30 min after dinner
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Moderate exercise for 30 min at 60 min after dinner
Number of subjects: 15
Study: 27405296

Group type: EXPERIMENTAL
Intervention: Extended-release niacin/laropiprant (ERN/LRPT)
Number of subjects: 796

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 796
Study: 25440230

Group type: EXPERIMENTAL
Intervention: Intervention group (geographically isolated EDs)
Number of subjects: 307

Group type: COMPARATOR
Intervention: Control group (non-isolated EDs)
Number of subjects: 307
Study: 22592864

Group type: EXPERIMENTAL
Intervention: Frovatriptan 2.5 mg
Number of subjects: 67

Group type: COMPARATOR
Intervention: Almotriptan 12.5 mg
Number of subjects: 67
Study: 20173677

Group type: EXPERIMENTAL
Intervention: Recombivax HB (10 microg hepatitis B surface antigen)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Twinrix (20 microg hepatitis B surface antigen and 720 EL.U hepatitis A antigen)
Number of subjects: 123
Study: 18623197

Group type: EXPERIMENTAL
Intervention: Levothyroxine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 16182896

Group type: EXPERIMENTAL
Intervention: Single 20 mg/kg dose of ciprofloxacin
Number of subjects: 180

Group type: COMPARATOR
Intervention: 12.5 mg/kg of erythromycin every 6 h for 3 days
Number of subjects: 180
Study: 12468135

Group type: EXPERIMENTAL
Intervention: 1 mg E(2) and 0.5 mg NETA for 28 days
Number of subjects: 446

Group type: COMPARATOR
Intervention: 0.625 mg CEE for 28 days and 5 mg MG for the final 14 days
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: 1 mg E(2) and 0.5 mg NETA
Number of subjects: 446
Study: 12840859

Group type: EXPERIMENTAL
Intervention: Chanlibao (CLB)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Oxytocin (OTC)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Control (natural labor, no drug)
Number of subjects: 161